Physician profile
Miguel Antonio Busquets
NPI 1427054808
$91,898.52
in general payments reported to CMS, 2019-2025
22 companies · $49K in 2025
The $49K reported for 2025 was more than what 97% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.70 · 2020: $450 · 2021: $1,358 · 2022: $4,635 · 2023: $17K · 2024: $19K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $54K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,890 · Food and Beverage: $4,304 · Travel and Lodging: $4,154 · Honoraria: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $53,622.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,072.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,890.00 |
| Food and Beverage | $4,303.81 |
| Travel and Lodging | $4,153.94 |
| Honoraria | $1,390.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $44,095.99 | 2020-2025 | Unity, Constellation, Ngenuity |
| Apellis Pharmaceuticals, INC. | $16,111.11 | 2022-2025 | Syfovre |
| Carl Zeiss Meditec USA, INC. | $14,155.63 | 2022-2025 | Iolmaster 700, Humphrey Hfa, Forum |
| Alcon Research LLC | $10,212.92 | 2023-2025 | Ngenuity |
| Alimera Sciences, INC. | $1,937.23 | 2020-2024 | Iluvien, Yutiq |
| Harrow Eye, LLC | $1,432.18 | 2025 | Triesence, Iheezo |
| Notal Vision, INC. | $799.96 | 2021-2025 | Foresee Home |
| Optos, INC. | $691.53 | 2021-2022 | |
| Genentech USA, INC. | $559.16 | 2021-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $517.44 | 2020-2025 | Eylea, Eylea Hd, Dupixent |
| Astellas Pharma US INC | $323.21 | 2024-2025 | Izervay |
| Abbvie INC. | $280.36 | 2022-2025 | Ozurdex |
| Allergan, INC. | $152.05 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $150.19 | 2020-2021 | |
| Alcon Puerto Rico INC | $131.93 | 2025 | Unity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $100.48 | 2025 | Dextenza |
| Biogen, INC. | $85.77 | 2022-2024 | Byooviz |
| Ani Pharmaceuticals, INC. | $57.97 | 2025 | Yutiq, Purified Cortrophin Gel |
| Genentech, INC. | $56.67 | 2025 | Vabysmo |
| Eyepoint US, INC. | $24.04 | 2022 | |
| Sun Pharmaceutical Industries INC. | $22.70 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Busquets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.